Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Profile of suvorexant in the management of insomnia
Eliza L. Sutton
Drug Design Development and Therapy (2015), pp. 6035-6035
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study
Patricia Murphy, Margaret Moline, David Mayleben, et al.
Journal of Clinical Sleep Medicine (2017) Vol. 13, Iss. 11, pp. 1289-1299
Open Access | Times Cited: 298
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Ying Han, Kai Yuan, Yongbo Zheng, et al.
Neuroscience Bulletin (2019) Vol. 36, Iss. 4, pp. 432-448
Open Access | Times Cited: 77
Clinical specificity profile for novel rapid acting antidepressant drugs
Mauro Scala, Giuseppe Fanelli, Diana De Ronchi, et al.
International Clinical Psychopharmacology (2023) Vol. 38, Iss. 5, pp. 297-328
Open Access | Times Cited: 26
Prefrontal Cortical Opioids and Dysregulated Motivation: A Network Hypothesis
Brian A. Baldo
Trends in Neurosciences (2016) Vol. 39, Iss. 6, pp. 366-377
Open Access | Times Cited: 75
Effects of orexin receptor antagonism on human sleep architecture: A systematic review
Jacob Clark, Maddison L. Brian, Sean P. A. Drummond, et al.
Sleep Medicine Reviews (2020) Vol. 53, pp. 101332-101332
Closed Access | Times Cited: 54
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications
W. Joseph Herring, Thomas Roth, Andrew D. Krystal, et al.
Journal of Sleep Research (2018) Vol. 28, Iss. 2
Closed Access | Times Cited: 44
Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation
Carsten T. Beuckmann, Takashi Ueno, Makoto Nakagawa, et al.
SLEEP (2019) Vol. 42, Iss. 6
Open Access | Times Cited: 38
Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials
Margaret Moline, Gary Zammit, Jane Yardley, et al.
Postgraduate Medicine (2020) Vol. 133, Iss. 1, pp. 71-81
Open Access | Times Cited: 36
Role of orexin in pathogenesis of neurodegenerative parkinsonisms
Piotr Alster, Natalia Madetko, Dagmara Otto‐Ślusarczyk, et al.
Neurologia i Neurochirurgia Polska (2023) Vol. 57, Iss. 4, pp. 335-343
Open Access | Times Cited: 9
Timed Inhibition of Orexin System by Suvorexant Improved Sleep and Glucose Metabolism in Type 2 Diabetic db/db Mice
Hiroshi Tsuneki, Kanta Kon, Hisakatsu Ito, et al.
Endocrinology (2016) Vol. 157, Iss. 11, pp. 4146-4157
Open Access | Times Cited: 30
Improvement of glycemic control by treatment for insomnia with suvorexant in type 2 diabetes mellitus
Norikazu Toi, Masaaki Inaba, Masafumi Kurajoh, et al.
Journal of Clinical & Translational Endocrinology (2018) Vol. 15, pp. 37-44
Open Access | Times Cited: 29
Fatal acute lemborexant Poisoning: An autopsy case report
Gentaro Yamasaki, Yasuhiro Ueno, Motonori Takahashi, et al.
Legal Medicine (2024) Vol. 71, pp. 102527-102527
Closed Access | Times Cited: 2
Daridorexant for the treatment of insomnia disorder: findings and implications
Jéssica Barreto Ribeiro dos Santos, Michael Ruberson Ribeiro da Silva
European Journal of Clinical Pharmacology (2022) Vol. 78, Iss. 11, pp. 1749-1761
Closed Access | Times Cited: 12
Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis
Tao Xue, Xin Wu, Jiaxuan Li, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
Neurophysiological and Behavioral Effects of Anti-Orexinergic Treatments in a Mouse Model of Huntington's Disease
Magali Cabanas, Cristiana Pistono, Laura Puygrenier, et al.
Neurotherapeutics (2019) Vol. 16, Iss. 3, pp. 784-796
Open Access | Times Cited: 19
Suvorexant-Induced Dream Enactment Behavior in Parkinson Disease: A Case Report
Hiromitsu Tabata, Akira Kuriyama, Fusae Yamao, et al.
Journal of Clinical Sleep Medicine (2017) Vol. 13, Iss. 05, pp. 759-760
Open Access | Times Cited: 17
Effect of Suvorexant on Nocturnal Delirium in Elderly Patients with Alzheimer’s Disease: A Case-series Study
Tomoki Hanazawa, Yoshito Kamijo
Clinical Psychopharmacology and Neuroscience (2019) Vol. 17, Iss. 4, pp. 547-550
Open Access | Times Cited: 15
Direct activation of G-protein-gated inward rectifying K+ channels promotes nonrapid eye movement sleep
Bende Zou, William Cao, Zhiwei Guan, et al.
SLEEP (2018) Vol. 42, Iss. 3
Open Access | Times Cited: 14
Is schedule IV suvorexant an appropriate reference drug of abuse to use in preclinical abuse liability testing in the rat?
Greet Teuns, Michela Tessari
Regulatory Toxicology and Pharmacology (2024) Vol. 148, pp. 105570-105570
Open Access | Times Cited: 1
Tissue Distribution of Suvorexant in Three Forensic Autopsy Cases
Brian Waters, Kenji Hara, Natsuki Ikematsu, et al.
Journal of Analytical Toxicology (2017) Vol. 42, Iss. 4, pp. 276-283
Open Access | Times Cited: 12
Classification of Parasomnias
Louis Kazaglis, Michel A. Cramer Bornemann
Current Sleep Medicine Reports (2016) Vol. 2, Iss. 2, pp. 45-52
Open Access | Times Cited: 10
Transitioning insomnia patients from zolpidem to lemborexant: A multicenter, open-label study evaluating a next-dose transition approach to insomnia pharmacotherapy
Maha Ahmad, James Kelly, C. Brendan Montano, et al.
Sleep Medicine X (2023) Vol. 7, pp. 100098-100098
Open Access | Times Cited: 3
In Vitro and In Vivo Evaluation of Pellotine: A Hypnotic Lophophora Alkaloid
Christian B. M. Poulie, Camilla B. Chan, Aleksandra Parka, et al.
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 10, pp. 1492-1507
Open Access | Times Cited: 3
Evaluating lemborexant for the treatment of insomnia
Gary Zammit, Andrew D. Krystal
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 10, pp. 1235-1243
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top